~~<i id='8A15C6DD04'><strike id='8A15C6DD04'><tt id='8A15C6DD04'><pre id='8A15C6DD04'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

entertainment

author：explore 2025-08-05 16:31:41 - browse：677

Alkermes shareholders voted Thursday to re-elect all of the drugmaker’s current directors, ending an acrimonious proxy fight with hedge fund Sarissa Capital Management, which had sought to seat three directors on the board.

At the company’s annual meeting, shareholders voted in favor of Alkermes’ proposal to retain all seven of the director nominees to the 11-person board.

The outcome is a setback for Sarissa, which owns 8.5% of Alkermes and is run by activist investor Alex Denner. Sarissa has accused Alkermes executives of mismanaging the business and destroying shareholder value.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： David Liu startup to focus on CRISPR delivery

explore

knowledge

hotspot

knowledge

AdobeHealthinsurersaretellingshareholdersthattheyarerampinguptheuseofartificialintelligenceandarehir

WSS

Insmed lung disease drug hits target in key Phase 3 trial

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Health insurers say they are turning to AI to cut costs, improve care

Fed up with FDA, ALS advocates consider a take

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Assistant physicians can help address the primary care shortage

focus

entertainment

explore

ChatGPT in medicine: STAT answers readers' burning questions

'A game

At least 13 dead in Texas as scorching temps continue

Average age of first period drops to 11.9 years, study shows

23andMe had bad news about my health. I wish a person had delivered it

Stigma and the return of syphilis

In age of alternative facts, a scholarly course on calling out crap

iTeos Therapeutics debuts first data on TIGIT

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Grad students accuse University of California of wage theft

knowledge

Grad students accuse University of California of wage theft

House panel takes first step toward fixing drug shortages

Health insurers say they are turning to AI to cut costs, improve care

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

Stigma and the return of syphilis

hotspot

hotspot

hotspot

knowledge